Please Wait.....
Report
Global Neurology Clinical Trials Market Report and Forecast 2024-2032
Market Report I 2023-10-01 I 140 Pages I EMR Inc.
Global Neurology Clinical Trials Market Report and Forecast 2024-2032
Global Neurology Clinical Trials Market Outlook
The global neurology clinical trials market size was valued at USD 5.7 billion in 2023, driven by both their rising prevalence and the substantial unmet need for innovative treatments across the globe. The market size is anticipated to grow at a CAGR of 5.7% during the forecast period of 2024-2032 to achieve a value of USD 9.4 billion by 2032.
Neurology Clinical Trials: Introduction
Neurology clinical trials are specialized research studies designed to evaluate the safety and efficacy of new treatments, interventions, or diagnostic tools for neurological disorders. These disorders range from common conditions such as migraines and epilepsy to more complex diseases like Alzheimer's, Parkinson's, and multiple sclerosis. Given the intricacies of the nervous system and the profound impact of neurological conditions on patients' lives, these trials are crucial for advancing our understanding and developing effective therapeutic strategies.
Conducted under stringent guidelines and ethical considerations, neurology clinical trials often encompass various phases, from early-stage studies assessing safety to larger, multicentre trials evaluating therapeutic impact against standard treatments. As the quest to unravel the mysteries of the brain and its disorders continues, clinical trials in neurology serve as a linchpin, bridging the gap between novel scientific discoveries and tangible improvements in patient care.
Key Trends in the Global Neurology Clinical Trials Market
The global neurology clinical trials market has been characterized by an intensified focus on complex neurodegenerative disorders, such as Alzheimer's and Parkinson's. This surge is driven by both their rising prevalence and the substantial unmet need for innovative treatments. Concurrently, the adoption of biomarkers, like tau or beta-amyloid, is revolutionizing the landscape, facilitating enhanced diagnosis and precision in patient selection. The era of personalized medicine is dawning, with trials increasingly leveraging genomic insights to tailor treatments to specific patient profiles. Technological strides have enabled the integration of wearables and digital tools, ushering in opportunities for real-time, remote patient monitoring. This shift is complemented by an evolving paradigm towards patient-centric trial designs, aiming to enhance the patient experience and incorporate their feedback directly.
Multi-centre and international collaborations are fostering broader, more diverse patient representation and expediting recruitment, although the challenge of patient retention remains. Adaptive trial methodologies, which allow for in-trial adjustments based on interim results, are gaining traction for their efficiency. Furthermore, advancements in neuroimaging, including techniques like functional MRI, are offering unprecedented insights into disease progression and therapeutic impacts. Lastly, regulatory landscapes are evolving, with an increasing emphasis on real-world evidence, spotlighting the value of post-marketing studies and real-world data alongside traditional controlled trials.
Global Neurology Clinical Trials Market Segmentation
Market Breakup by Type
- Phase I
- Phase II
- Phase III
- Phase IV
Market Breakup by Indications
- Epilepsy
- Stroke
- Alzheimer's Disease (AD)
- Parkinson's Disease (PD)
- Others
Market Breakup by Study Design
- InterventionaL
- Observational
- Expanded Access
Market Breakup by Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Global Neurology Clinical Trials Market Overview
The global neurology clinical trials market is a dynamic and vital segment of the broader medical research landscape, focused on the evaluation of novel treatments, interventions, and diagnostic tools for neurological disorders. Ranging from common conditions such as migraines to intricate neurodegenerative diseases like Alzheimer's, the market's expanse is vast. The urgency to address the increasing prevalence of many of these conditions, especially given the aging global population, has catalyzed a surge in research and investment. Novel trial designs, leveraging cutting-edge technologies like digital tools, wearables, and advanced neuroimaging, are becoming the norm, offering deeper insights into disease progression and therapeutic efficacy.
Patient-centric approaches, emphasizing improved trial experience and direct feedback, are gaining momentum. Yet, challenges persist, especially concerning patient recruitment and retention, underscoring the need for heightened community awareness and education. Collaborative, multi-centre initiatives are increasingly bridging geographical divides, ensuring diverse patient representation and expediting the drug development process. The market's trajectory is further shaped by evolving regulatory standards, which increasingly value real-world evidence alongside traditional trial results. As scientific endeavours continue to unravel the complexities of the brain, the neurology clinical trials market stands at the forefront, translating these discoveries into tangible therapeutic advancements.
Global Neurology Clinical Trials Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Supernus Pharmaceuticals, Inc.
- AstraZeneca
- Aurobindo Pharma
- Eisai Co., Ltd.
- Eli Lilly and Company
- Aurora Health Care
- AbbVie Inc.
- Zydus Group
- Athira Pharma, Inc.
- Annovis Bio
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Global Neurology Clinical Trials Market Overview
3.1 Global Neurology Clinical Trials Market Historical Value (2017-2023)
3.2 Global Neurology Clinical Trials Market Forecast Value (2024-2032)
4 Global Neurology Clinical Trials Market Landscape
4.1 Global Neurology Clinical Trials: Developers Landscape
4.1.1 Analysis by Year of Establishment
4.1.2 Analysis by Company Size
4.1.3 Analysis by Region
4.2 Global Neurology Clinical Trials: Product Landscape
4.2.1 Analysis by Phase
4.2.2 Analysis by Indications
5 Global Neurology Clinical Trials Market Dynamics
5.1 Market Drivers and Constraints
5.2 SWOT Analysis
5.3 Porter's Five Forces Model
5.4 Key Demand Indicators
5.5 Key Price Indicators
5.6 Industry Events, Initiatives, and Trends
5.7 Value Chain Analysis
6 Global Neurology Clinical Trials Market Segmentation
6.1 Global Neurology Clinical Trials Market by Type
6.1.1 Market Overview
6.1.2 Phase I
6.1.3 Phase II
6.1.4 Phase III
6.1.5 Phase IV
6.2 Global Neurology Clinical Trials Market by Indications
6.2.1 Market Overview
6.2.2 Epilepsy
6.2.3 Stroke
6.2.4 Alzheimer's Disease (AD)
6.2.5 Parkinson's Disease (PD)
6.2.6 Others
6.3 Global Neurology Clinical Trials Market by Study Design
6.3.1 Market Overview
6.3.2 Interventional
6.3.3 Observational
6.3.4 Expanded Access
6.4 Global Neurology Clinical Trials Market by Region
6.4.1 Market Overview
6.4.2 North America
6.4.3 Europe
6.4.4 Asia Pacific
6.4.5 Latin America
6.4.6 Middle East and Africa
7 North America Neurology Clinical Trials Market
7.1 Market Share by Country
7.2 United States of America
7.3 Canada
8 Europe Neurology Clinical Trials Market
8.1 Market Share by Country
8.2 United Kingdom
8.3 Germany
8.4 France
8.5 Italy
8.6 Others
9 Asia Pacific Neurology Clinical Trials Market
9.1 Market Share by Country
9.2 China
9.3 Japan
9.4 India
9.5 ASEAN
9.6 Australia
9.7 Others
10 Latin America Neurology Clinical Trials Market
10.1 Market Share by Country
10.2 Brazil
10.3 Argentina
10.4 Mexico
10.5 Others
11 Middle East and Africa Neurology Clinical Trials Market
11.1 Market Share by Country
11.2 Saudi Arabia
11.3 United Arab Emirates
11.4 Nigeria
11.5 South Africa
11.6 Others
12 Regulatory Framework
12.1 Regulatory Overview
12.1.1 US FDA
12.1.2 EU EMA
12.1.3 INDIA CDSCO
12.1.4 JAPAN PMDA
12.1.5 Others
13 Grants Analysis
13.1 Analysis by year
13.2 Analysis by Amount Awarded
13.3 Analysis by Issuing Authority
13.4 Analysis by Grant Application
13.5 Analysis by Funding Institute
13.6 Analysis by NIH Departments
13.7 Analysis by Recipient Organization
14 Clinical Trials Analysis
14.1 Analysis by Trial Registration Year
14.2 Analysis by Trial Status
14.3 Analysis by Trial Phase
14.4 Analysis by Therapeutic Area
14.5 Analysis by Geography
15 Funding and Investment Analysis
15.1 Analysis by Funding Instances
15.2 Analysis by Type of Funding
15.3 Analysis by Funding Amount
15.4 Analysis by Leading Players
15.5 Analysis by Leading Investors
15.6 Analysis by Geography
16 Partnership and Collaborations Analysis
16.1 Analysis by Partnership Instances
16.2 Analysis by Type of Partnership
16.3 Analysis by Leading Players
16.4 Analysis by Geography
17 Supplier Landscape
17.1 Supernus Pharmaceuticals, Inc.
17.1.1 Financial Analysis
17.1.2 Product Portfolio
17.1.3 Demographic Reach and Achievements
17.1.4 Mergers and Acquisitions
17.1.5 Certifications
17.2 AstraZeneca
17.2.1 Financial Analysis
17.2.2 Product Portfolio
17.2.3 Demographic Reach and Achievements
17.2.4 Mergers and Acquisitions
17.2.5 Certifications
17.3 Aurobindo Pharma
17.3.1 Financial Analysis
17.3.2 Product Portfolio
17.3.3 Demographic Reach and Achievements
17.3.4 Mergers and Acquisitions
17.3.5 Certifications
17.4 Eisai Co., Ltd.
17.4.1 Financial Analysis
17.4.2 Product Portfolio
17.4.3 Demographic Reach and Achievements
17.4.4 Mergers and Acquisitions
17.4.5 Certifications
17.5 Eli Lilly and Company
17.5.1 Financial Analysis
17.5.2 Product Portfolio
17.5.3 Demographic Reach and Achievements
17.5.4 Mergers and Acquisitions
17.5.5 Certifications
17.6 Aurora Health Care
17.6.1 Financial Analysis
17.6.2 Product Portfolio
17.6.3 Demographic Reach and Achievements
17.6.4 Mergers and Acquisitions
17.6.5 Certifications
17.7 AbbVie Inc.
17.7.1 Product Portfolio
17.7.2 Demographic Reach and Achievements
17.7.3 Mergers and Acquisitions
17.7.4 Certifications
17.8 Zydus Group
17.8.1 Financial Analysis
17.8.2 Product Portfolio
17.8.3 Demographic Reach and Achievements
17.8.4 Mergers and Acquisitions
17.8.5 Certifications
17.9 Athira Pharma, Inc.
17.9.1 Financial Analysis
17.9.2 Product Portfolio
17.9.3 Demographic Reach and Achievements
17.9.4 Mergers and Acquisitions
17.9.5 Certifications
17.10 Annovis Bio
17.10.1 Financial Analysis
17.10.2 Product Portfolio
17.10.3 Demographic Reach and Achievements
17.10.4 Mergers and Acquisitions
17.10.5 Certifications
18 Key Opinion Leaders (KOL) Insights (Additional Insight)
19 Company Competitiveness Analysis (Additional Insight)
19.1 Very Small Companies
19.2 Small Companies
19.3 Mid-Sized Companies
19.4 Large Companies
19.5 Very Large Companies
20 Payment Methods (Additional Insight)
20.1 Government Funded
20.2 Private Insurance
20.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security